EDSANasdaqPharmaceutical PreparationsFiscal year ends September 30
Edesa Biotech, Inc.
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$2.78+0.21 (+8.17%)
Close on Oct 19, 2026
- Market cap
- $25.04M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$0.42 (+17.93%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $25.04M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.84
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$14.10M
- EPS, diluted
- -$1.69
- Book value per share
- $0.98
- Diluted shares
- 9M
Fourteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
–
Gross profit
–
Operating income
-$14.63M
Net income
-$14.10M
EPS, diluted
-$1.69
Free cash flow
–
Reported periodTrailing twelve months